Robert W. Baird analyst Michael Polark maintained a Hold rating on Resmed (NYSE:RMD) on Friday, setting a price target of $260, which is approximately 5.35% below the present share price of $274.69.
Polark expects Resmed to post earnings per share (EPS) of -$0.54 for the third quarter of 2021.
The current consensus among 10 TipRanks analysts is for a Hold rating of shares in Resmed, with an average price target of $220.54.
The analysts price targets range from a high of $270 to a low of $26.32.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $768.77 million and a net profit of $223.43 million. The company's market cap is $39.97 billion.
According to TipRanks.com, Robert W. Baird analyst Michael Polark is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 16.0% and a 71.43% success rate.
Founded in 1989, California-based ResMed, Inc. is a medical equipment company. The company is engaged in the development, manufacturing, distribution, and marketing of medical equipment and software solutions. The company operates through two segments: Sleep and Respiratory Care, and SaaS (Software as a Service).